Equasens Reports Impressive Q1 Revenue Growth
Equasens Group, a leader in digital healthcare solutions, has reported remarkable revenue figures for the first quarter of the year. The company closed out the quarter with a revenue of €57.0 million, reflecting a growth of 6.9% compared to Q1 of the previous year. When looking strictly at like-for-like figures, the growth stood at 5.9%, showcasing a steady upward trajectory.
Revenue Breakdown Across Divisions
Pharmagest Division
The Pharmagest Division generated €42.0 million in revenue, marking a 5.5% increase. This growth can be attributed to several factors including enhanced demand for innovative solutions, especially in France where all business lines experienced positive growth. New functionalities introduced in their software offerings have been well received, contributing to the overall revenue growth.
Axigate Link Division
The Axigate Link Division recorded a revenue of €8.3 million, a commendable increase of 5.5%. This was driven by continued success within the Nursing Home sector, bolstered by public funding initiatives. Furthermore, recent contract signings in the Homecare sector suggest promising future growth.
E-Connect Division
Revenue from the E-Connect Division surged to €3.5 million, demonstrating a striking growth of 21.2%. The significant rebound in sales of their mobility solutions played a critical role in this division's performance, aided by national initiatives regarding health insurance applications.
Medical Solutions Division
Equasens's Medical Solutions Division reported revenues of €2.7 million, which reflects a 25.1% increase. A major contributor to this achievement was the acquisition of CALIMED, which has proved beneficial in extending their SaaS offerings.
Fintech Division Performance
Conversely, the Fintech Division reported a slight decline in revenue to €0.6 million, down 8.3%. This decrease is related to strategic restructuring efforts aimed at improving portfolio quality and minimizing risk exposure. Despite this, the division continues to generate promising leads.
Future Outlook and Growth Strategies
As we move forward in 2025, Equasens Group remains optimistic about its growth potential, especially in the pharmacy sector where renewed confidence among pharmacists is evident. Expecting continued momentum from Q1, the company plans to maintain its pace of investment towards innovative digital solutions. Key strategies will focus on expanding their SaaS offerings and fostering external growth opportunities, both domestically and across Europe.
Financial Calendar Highlights
Key dates for investors and stakeholders are fast approaching, with the Annual General Meeting scheduled for late June. Further, the second quarter revenue metrics will be revealed at the end of July, presenting a timely opportunity to gauge ongoing performance.
About Equasens Group
With over three decades of industry presence, Equasens Group leads the charge in delivering digital solutions for healthcare professionals. The company is recognized for its commitment to harnessing technology to improve medical practices and patient care significantly. With a dedicated team of over 1,300 employees across Europe, Equasens not only offers tailored business applications but also supports health professionals in transitioning to digital formats.
Contact Information
Equasens Group
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67
Email: frederique.schmidt@equasens.com
Financial Communications Agency: FIN’EXTENSO - Isabelle Aprile
Tel: +33 (0)6 17 38 61 78
Email: i.aprile@finextenso.fr
Frequently Asked Questions
What was Equasens Group's total revenue for Q1 2025?
Equasens Group reported a total revenue of €57.0 million for the first quarter of 2025.
Which division of Equasens showed the highest growth?
The Medical Solutions Division exhibited the highest growth at 25.1% due to the integration of CALIMED products.
How does the Fintech Division's performance compare to other divisions?
The Fintech Division had a decline of 8.3% in revenue, which contrasts with the growth seen in other divisions.
What are the growth prospects for Equasens in the upcoming quarters?
Equasens is optimistic about continued growth, particularly in the pharmacy sector, driven by high demand and promising customer sentiments.
Which key dates should investors note in the financial calendar?
Investors should note the Annual General Meeting on June 25, 2025, and the Q2 revenue report on July 31, 2025.
